There’s so much news from media outlets and bloggers about the next Health Tech investment treads that its difficult to pin point where to focus or what will materialize.
Its much easier when you can actually hear the treads from the investors who are shaping the industry – well Health 2.0 got you covered! At next week’s WinterTech conference, we’re featuring the 4 CEOs and Their VCs panel session.
A spin-off of the popular 3 CEOs session from the Fall Conference, the 4 CEOs and Their VCs session is made up of four, back-to-back interviews between digital health CEOs and the VCs who believe in them. Hear exclusive insight into what’s happening in health tech investments with conversations between:
  • Venrock and Robin: Robin is a brand new digital assistant for doctors. Hear Venrock Partner Bryan Roberts and Robin CEO Punit Son discuss the opportunities Venrock sees in Robin.
  • 415 and Lemonaid: Patient experience has gotten easier with Lemonaid’s accessible online platform. Lemonaid CEO Paul Johnson sits with investment firm 415 to talk about their business strategy.
  • Thrive Capital and Honor: An online service that connects in-home caregivers, seniors and their families, Honor sits down with its investor Thrive Capital to discuss the purpose of their investment.
  • Grandrounds and Venrock: Owen Tripp of Grandrounds and Bob Kocher of Venrock discuss their working partnership, and give insight into what those closed-door meetings look like.
From Seed to Series C, don’t miss the opportunity to join the session that is representing each unique stage of the investment cycle. Tickets are selling fast so register today!


from THCB http://ift.tt/2lK2kMi

Related Posts:

  • Will Amazon Eat the Market?By PAUL KECKLEY Last Tuesday, a trio of corporate heavy weights announced they were joining forces to fix the U.S. healthcare system. The CEOs of the three—Jeff Bezos of Amazon, Warren Buffet of Berkshire Hathaway, and Jamie … Read More
  • The Optimistic OncologistBy BISHAL GYAWALI, MD Why conduct post approval studies at all? Atezolizumab previously received accelerated approval in second-line metastatic or advanced urothelial cancer based on response rates from a singl… Read More
  • It’s (Still) the Prices, StupidBy SETH HARDY Inefficient markets create price differentials for identical goods. These price differentials frequently occur among markets dominated by oligopolies. Taking advantage of market pricing inefficiencies is known a… Read More
  • Sexism in Healthcare ReportingBy NIRAN AL-AGBA, MD NBC should consider re-branding as the “anti-woman” network.  Our culture needs to change so women feel valued and respected, comfortable and safe in the workplace, and are provided ample opportunit… Read More
  • Medicine Is a Profession That is Rapidly Losing Control of Its Tools.By ADRIAN GROPPER, MD Artificial Intelligence hype and reality are everywhere. However, the last month or two has seen some thoughtful reflection. HHS / ONC announced “Hype to Reality: How Artificial Intelligence (AI) Can Tra… Read More

0 comments:

Post a Comment

Popular Posts